Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy
- 25 January 2002
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 50 (3) , 179-188
- https://doi.org/10.1002/pros.10047
Abstract
BACKGROUND: Progression of prostate cancer to androgen independence (AI) results in part from the upregulation of anti‐apoptotic genes following androgen withdrawal, and androgen‐independent disease remains the primary obstacle to improved survival. Testosterone‐repressed prostate message‐2 (TRPM‐2) encodes the anti‐apoptotic protein clusterin, which is upregulated in response to cellular compromise as observed in normal and malignant tissues undergoing apoptosis. Systemic administration of antisense clusterin oligonucleotides in prostate cancer xenograft models delays progression to AI and enhances chemosensitivity. The objective of this study was to define changes in clusterin expression following neoadjuvant hormone therapy (NHT) in prostate cancer patients.MATERIALS AND METHODS: Archival radical prostatectomy (RP) specimens were obtained for 128 patients who received either no NHT or treatment for 2–8 weeks, 3 months, or 8 months. Paired needle biopsy specimens were acquired for 30 patients and all tissues were subjected to clusterin immunohistochemistry. Western blot analysis was performed on frozen tissue from 5 untreated and 5 treated patients.RESULTS: Clusterin expression in malignant prostatic tissue was significantly greater in patients who underwent preoperative NHT (P ≪ 0.001). Needle biopsies obtained prior to NHT consistently demonstrated lower staining intensity than corresponding RP specimens (P ≪ 0.001). Western blot analysis confirmed clusterin levels increased 17‐fold beginning within 4 weeks after androgen withdrawal.CONCLUSIONS: Upregulation of clusterin levels following androgen ablation therapy may represent an adaptive cell survival response following apoptotic signals like androgen withdrawal. These findings support clusterin as a valid therapeutic target in strategies employing novel multimodality therapy for advanced prostate cancer. Prostate 50: 179–188, 2002.Keywords
This publication has 33 references indexed in Scilit:
- Transforming growth factor β regulates clusterin gene expression via modulation of transcription factor c‐FosEuropean Journal of Biochemistry, 1999
- Transforming Growth Factor β-1 Up-Regulates Clusterin Synthesis in Thyroid Epithelial CellsExperimental Cell Research, 1999
- An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosisCell Death & Differentiation, 1999
- Maintenance of Calcium Homeostasis in the Endoplasmic Reticulum by Bcl-2The Journal of cell biology, 1997
- Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate CancerJournal of Urology, 1996
- Clusterin promotes the aggregation and adhesion of renal porcine epithelial cells.Journal of Clinical Investigation, 1995
- Studies on the relationship between cell proliferation and cell death: Opposite patterns of SGP-2 and ornithine decarboxylase mRNA accumulation in pha-stimulated human lymphocytesBiochemical and Biophysical Research Communications, 1991
- In vivo accumulation of sulfated glycoprotein 2 mRNA in rat thymocytes upon dexamethasone-induced cell deathBiochemical and Biophysical Research Communications, 1991
- Characterization and cloning of androgen-repressed mRNAs from rat ventral prostateBiochemical and Biophysical Research Communications, 1987
- Androgen‐repressed messages in the rat ventral prostateThe Prostate, 1986